All
ASDS: Review of Lasers and Light-Based Therapies for Acne
New technologies such as the 1726-nm laser and pneumatic assisted broad band light are emerging treatments in acne.
FDA Accepts sBLA for Interchangeability Designation for Adalimumab-bwwd
HADLIMA is currently indicated for psoriatic arthritis, plaque psoriasis, and hidradenitis suppurativa, among others.
TAK-279 Shows Significant Efficacy in Phase 2b Psoriatic Arthritis Study
Investigators report 12 weeks of treatment provided a strong foundation for further evaluation of TAK-279 across the psoriatic arthritis disease spectrum.
Dermatologists Play Crucial Role in Support and Inclusivity of Transgender and Gender-Diverse Patients
Understanding the needs of gender-diverse patients and patients receiving gender-affirming hormones is crucial to equitable care and properly addressing patients' needs.
POLL: Which of the Following 2023 NP & PA Conferences Has Been Your Favorite?
Click here to answer this week's NP & PA poll. Out of the meetings listed below, which one did you enjoy the most?
Combined With NB-UVB Therapy, Topical Vitamin D May Enhance Therapeutic Outcomes of Vitiligo
Incorporating vitamin D may mitigate adverse effects of corticosteroids, though more research is needed to discover the best methods for topical administration in vitiligo.
Older, Middle-Aged Adults With Atopic Dermatitis Face an Increased Risk of Cognitive Dysfunction
Study authors urge clinicians to screen adult patients with AD for cognitive dysfunction.
Proposed FDA Ban of Formaldehyde in Hair Relaxers: What Comes Next?
Christopher Bunick, MD, PhD, and David Light, CEO of Valisure, weigh in on the proposed formaldehyde ban.
Meta-Analysis Finds Chinese Patent Medicines May Be Efficacious, Suitable Interventions for Vitiligo
Combined with routine treatments for vitiligo, certain CPMs proved efficacious in patients with vitiligo, with few adverse effects.
The Cutaneous Connection: Pearls for Atopic Dermatitis in College-Aged Patients
In this episode, discover and learn how to address the unique challenges faced by college students diagnosed with atopic dermatitis—especially as they navigate new lifestyles and medication management.
Mohs Surgery Improves Rates of Nodal Metastasis and Disease Specific Death in cSCC
Study results were presented at the 2023 American Society for Dermatologic Surgery Annual Meeting in Chicago, Illinois.
Derm In The News: October 29-November 4
Keep up with the latest headlines in dermatology from the past week, including the development of a synthetic biomimetic melanin, the potential for a shortage of minoxidil, and more.
Understanding Biologic Options in Atopic Dermatitis Management
Test your knowledge on approved biologics in the management of moderate to severe atopic dermatitis and considerations for an 18-year-old man's case.
The Weekly Roundup: October 29-November 3
ICYMI, this week we had articles about World Psoriasis Day, the FDA approval of secukinumab for hidradenitis suppurativa, positive data of delgocitinib cream for chronic hand eczema, and more.
Exploring the Potential of Polyphenols in Dermatology
Polyphenols, found in certain foods, have antioxidant and anti-inflammatory properties may help modulate immune responses, offering potential adjunctive therapy for atopic dermatitis, psoriasis, and chronic urticaria.
Acne Survey Reveals Only 3 in 10 Patients Have Gone to a Dermatologist for Treatment
The Sun Pharma survey included 1003 respondents with mild to moderate acne.
Psoriasis Patients With Pruritis, Sleep Impairments Demonstrate Lower Quality of Life in All Domains
PASI scores were significantly correlated with sleep quality, duration, and disturbances.
Proteomic Analysis Reveals Potential Differences in Patients Achieving VASI 50 Improvements VS Those Who Do Not
Investigators believe different circulating inflammatory phenotypes in patients with vitiligo may influence their responses to treatment with ruxolitinib cream.
LEO Pharma Announces Positive Results for Delgocitinib Cream for Chronic Hand Eczema
Delgocitinib is first-in-class pan-Janus kinase inhibitor.
Long-Term Safety of Dupilumab in Adults with Moderate to Severe Atopic Dermatitis
The results from this 5-year open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.
Patient With Plaque Psoriasis and Accompanying End-Stage Renal Disease Treated With Adalimumab
Authors of the case report that little is known about the associations between psoriasis and renal function.
Lebrikizumab Maintains Skin Clearance for 2 Years in Atopic Dermatitis
Almost 80% of patients in an extension study maintained clear or almost clear skin, and 90% of patients saw continued improvements in itch.
POLL: Do You Utilize the 40-GEP Test for High Risk cSCC?
Click here to answer this week's skin cancer poll.
Review Finds Topical Erythromycin, Azithromycin, and Metronidazole Most Common Treatments for Pediatric Rosacea
Additionally, investigators found that several patients in the review had rosacea induced or exacerbated by the use of topical corticosteroids on the face.
Pointers With Portela: Hair Transplant Risks
In this week’s Pointers With Portela, the 208SkinDoc explains the hidden risks associated with hair transplants.
FDA Approves Ustekinumab-auub as Interchangeable Biosimilar to Stelara for Plaque Psoriasis, Psoriatic Arthritis, and More
The approved indication makes Wezlana the first approved interchangeable biosimilar to Stelara.
ChatGPT Performs Well in Actinic Keratosis Pathogenesis and Risk Factor Knowledge, Lacks in Diagnosis and Treatment
ChatGPT shows promise in dermatology but needs improvement in accuracy and conciseness for reliable clinical use, according to a study evaluating its performance in actinic keratosis management.
AI-Based Color Constancy Algorithm Improves Dermoscopy, Clinical Care
A comparative study revealed that color constancy algorithms reduce the variability of dermoscopy image quality, leading to positive outcomes for practitioners.
Discovering Dermatology Times: October 2023
Learn more about the in-depth topics covered in the October 2023 print issue of Dermatology Times.
FDA Approves Secukinumab for Hidradenitis Suppurativa
Secukinumab is currently the only IL-17A inhibitor approved for the condition.